Review Article
The Diagnostic Performance of Afirma Gene Expression Classifier for the Indeterminate Thyroid Nodules: A Meta-Analysis
Table 4
Pathological diagnoses at resection of Afirma results with cytological subtypes (N=225).
| | | | Pathological Diagnoses after Surgery | | Benign | | Malignant | |
| | FNA Diagnosis | No.(%) | Diagnosis | No.(%) | Diagnosis | No.(%) |
| | Bethesda III (AUS/FLUS) | 139(61.8%) | Follicular adenoma | 14(10.1%) | cvPTC | 37(26.6%) | | Adenomatoid nodule | 23(16.5%) | fvPTC | 34(24.5%) | | Thyroiditis | 7(5.0%) | PTC with HC | 2(1.4%) | | Graves’ Disease | 2(1.4%) | feature | | | HCA | 4(2.9%); | FTC | 1(0.7%) | | Chronic inflammation | 1(0.7%) | HCC | 1(0.7%) | | Nodular hyperplasia | 12(8.6%) | Others | 1(0.7%) | | Total | 63 | Total | 76 |
| | Bethesda IV (FN) | 77(34.2%) | Follicular adenoma | 10(13.0%) | cvPTC | 25(28.6%) | | HCA | 17(22.1%) | fvPTC | 13(16.9%) | | Adenomatoid nodule | 6(7.8%) | FTC | 1(1.3%) | | Nodular hyperplasia | 1(1.3%) | HCC | 4(5.2%) | | Total | 34 | Total | 43 |
| | Bethesda V (SM) | 9(4.0%) | None | | fvPTC | 7(5.5%) | | Total | 0 | Others | 2(1.6%) | | | | Total | 9 |
| | All Categories | 225(100.0%) | | 97 | | 128 |
|
|
PTC, papillary thyroid carcinoma; FTC: follicular thyroid carcinoma; MTC: medullary thyroid cancer; AN, adenomatous/hyperplasic nodule; cvPTC, classic variant of papillary thyroid carcinoma; fvPTC, follicular variant of papillary thyroid carcinoma; NIFPTC, noninvasive follicular neoplasm with papillary-like nuclear features; PTC, HC feature; HCA, Hürthle cell adenoma; HCC, Hürthle cell carcinoma.
|
